(Q47717420)
Statements
Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis (English)
Shota Saito
Utako Shimizu
Zhang Nan
Nozomu Mandai
Junji Yokoyama